Periodontitis, AdultNCT06351722
Non-surgical Periodontal Treatment in Smokers on SIRT-1, NLRP3 Inflammasome and LncRNAs
An observational study of Periodontitis, Adult, run by Necmettin Erbakan University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational is to analyze the relationship between levels of interleukin-18 (IL-18), interleukin (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), interleukin-10 (IL-10), transforming growth factor beta (TGF-β), Nucleotide-binding oligomerization domain -like receptor protein 3 (NLRP3)… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontitis, Adult
- What is being tested?
- Before non-surgical periodontal treatment, non-surgical periodontal treatment and 3rd month after non-surgical periodontal treatment
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 100 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 25 Jun 2024to 15 Jul 2026
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: This study is planned to be conducted with 100 individuals aged between 18 and 65 who apply to the Department of Periodontology, Faculty of Dentistry, Necmettin Erbakan University, for various reasons. The eligibility of individuals to be included in the study will be evaluated by Dr. Zeynep TAŞTAN EROĞLU at the Periodontology Clinic of NEU Faculty of Dentistry.
Who may be able to join
- Being between the ages of 18 and 65
- Being diagnosed as "periodontally healthy" or "periodontitis" based on periodontal examination
- Not having any accompanying systemic diseases (such as diabetes, cardiovascular diseases, etc.)
- Agreeing to participate in the study
Who cannot join
- Use of contraceptive medications
- Use of anti-inflammatory, antibiotic, immunosuppressive, or other medications - that could affect the study outcomes within the previous 6 months
- History of excessive alcohol consumption
- Pregnancy or breastfeeding
- Undergoing periodontal treatment within the previous 6 months
- Refusal to participate in the study
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Necmettin Erbakan University Faculty of Dentistry, Department of Periodontology
Konya
About this study
Official title: Effect of Non-surgical Periodontal Treatment in Smokers on SIRT-1 and Proteins of the NLRP3 Inflammasome and Long Noncoding RNAs
The goal of this observational is to analyze the relationship between levels of interleukin-18 (IL-18), interleukin (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), interleukin-10 (IL-10), transforming growth factor beta (TGF-β), Nucleotide-binding oligomerization domain -like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), caspase-1, Sirtuin 1 (SIRT-1), Long noncoding RNA (lncRNA) small nucleolar RNA host gene 5 (SNHG5), and maternally expressed gene 3 (MEG3) in saliva, serum, and peripheral mononuclear blood cell (PMBC)in patients with periodontitis and smokers, to examine the changes in these biomarkers after non surgical periodontal treatment (NSPT), and to evaluate potential confounders that may mediate this relationship.
The main questions it aims to answer are:
question 1: Is there a relationship between the biomarkers mentioned above and periodontitis and smoking? question 2:How do the above-mentioned biomarkers change after NSPT in smokers and non-smokers?
Read the detailed description
There will be 4 groups in the study: Non-smoking periodontitis (NSP), smoking periodontitis (SP), non-smoking healthy control (HC), and smoking healthy control (HCS).
The periodontitis groups in the study (NSP and SP) will include patients diagnosed with Stage II and III, generalized, Grade B, C periodontitis clinically based on the consensus report of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and systemically healthy individuals. Patients with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. Patients with periodontal disease-related tooth loss ≤4 teeth will be included. Disease progression rate will be graded as B or C Class based on direct evidence of disease progression confirmed by panoramic radiographs and evidence of indirect destruction proportional to biofilm accumulations. In the smoking periodontitis group (SP) and smoking healthy group (HCS), participants who reported smoking >10 cigarettes per day for >5 years will be included, while participants in the non-smoking groups (NSP and HC) will be those who reported never smoking.
Clinical Measurements and Non-surgical Periodontal Treatment
Saliva and serum samples will be collected from all patients initially and 3 months after NSPT. Clinical parameters will also be recorded initially and at the 3rd month. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing. Examiner calibration will be provided before starting the study on a small pilot population to achieve consistent intra-examiner accuracy. After the collection of baseline samples and clinical parameter records, all patients will receive initial periodontal treatment, including patient education, full-mouth scaling, and root planing (SRP), and oral hygiene instructions from the same experienced clinician (ZTE).
Laboratory Measurement
Each patient will be instructed to abstain from eating, drinking, and oral hygiene practices for 12 hours before sampling. Serum and saliva samples will be collected from each patient between 8:00 and 10:00 in the morning before dental examination.
Blood Sampling: In the scope of the study, a total of 5 mL of blood will be collected from the antecubital vein of each individual by an expert nurse from the Department of Periodontology.
For serum sampling, venous puncture will be performed, and blood samples will be collected, immediately cooled on ice, and centrifuged at 4°C (800 rpm for 10 minutes). After the collection of saliva samples, they will be centrifuged immediately at 4°C (1000 rpm for 2 minutes). Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time polymerase chain reaction (RT-PCR).
IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels in PMBC will be evaluated using RT-PCR. All analysis steps for each kit will be evaluated using the protocol recommended by the manufacturer.
Statistical Analysis:
Statistical analysis will be performed using commercially available software (SPSS version 22.0, SPSS). In this study, a significance value (p-value) of <0.05 will be used. This study is designed as a prospective controlled clinical trial. The sample size of the study was calculated using the R Statistical Language program (version 4.1.2; The R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org). It was planned to include at least 25 individuals in each group for One-Way Analysis of Variance analysis to be conducted with a significance level of 5%, statistical power of 80%, and effect size of 0.4 (Cohen's f=0.4) to determine if there is a significant difference in inflammatory factors between the study groups (smoking periodontitis, smoking periodontally healthy, non-smoking periodontitis, non-smoking periodontally healthy).
Longitudinal analyses will include data only from patients who complete the entire study protocol.
- Conditions
- Periodontitis, Adult
- Being tested
- Before non-surgical periodontal treatment, non-surgical periodontal treatment, 3rd month after non-surgical periodontal treatment
- Keywords
- periodontitis, smoking, NLRP3 inflammasome, SIRT1, non-coding RNA
- Medical subject headings
- Chronic Periodontitis, Periodontitis, Smoking
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Before non-surgical periodontal treatmentDiagnostic test
Clinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing.
Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR.
non-surgical periodontal treatmentProcedure or surgery
Treatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol.
3rd month after non-surgical periodontal treatmentDiagnostic test
All clinical and laboratory evaluations described under the heading "Before non-surgical periodontal treatment" will be repeated in the 3rd month after NSPT.
| Study group | Role | What they receive |
|---|---|---|
| Non-smoking periodontitis (NSP) | participants who reported never smoking, with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. Receives: Diagnostic Test: Before non-surgical periodontal treatment; Procedure: non-surgical periodontal treatment; Diagnostic Test: 3rd month after non-surgical periodontal treatment | |
| smoking periodontitis (SP) | participants who reported smoking >10 cigarettes per day for >5 years with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. Receives: Diagnostic Test: Before non-surgical periodontal treatment; Procedure: non-surgical periodontal treatment; Diagnostic Test: 3rd month after non-surgical periodontal treatment | |
| non-smoking periodontal health (HC) | participants who reported never smoking and periodontal healthy. Receives: Diagnostic Test: Before non-surgical periodontal treatment | |
| smoking periodontal health (HCS) | participants who reported smoking >10 cigarettes per day and periodontal healthy. Receives: Diagnostic Test: Before non-surgical periodontal treatment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pre-treatment clinical and laboratory evaluation
Comparison of clinical measurements and IL-18, IL-1beta, TNF-alpha, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels of the 4 groups in the study
Measured: baseline
Comparison of clinical measurements and laboratory measurements at 3 months post-treatment
Comparison of clinical measurements and IL-18, IL-1beta, TNF-alpha, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels of periodontitis groups (NSP and SP) at the 3rd month after treatment
Measured: 3rd month after NSPT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2024
- Study start25 Jun 2024
- Primary completion15 Dec 2025
- Study completion15 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontitis, AdultStudies of the same condition, open and under way.
- More trials run by Necmettin Erbakan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 100 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Necmettin Erbakan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zeynep Tastan Eroglu, Necmettin Erbakan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06351722
- Sponsor's protocol ID
- smokingnlrp3inflasome
- Status last verified
- Aug 2026
- First submitted
- 2 Apr 2024
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Non-surgical Periodontal Treatment in Smokers on SIRT-1 and Proteins of the NLRP3 Inflammasome and Long Noncoding RNAs
- ClinicalTrials.gov ID
- NCT06351722
- Acronym / sponsor ID
- smokingnlrp3inflasome
- Conditions
- Periodontitis, Adult
- Keywords
- periodontitis, smoking, NLRP3 inflammasome, SIRT1, non-coding RNA
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Necmettin Erbakan UniversityUniversity, hospital or other
- Study start
- 25 Jun 2024 (actual)
- Primary completion
- 15 Dec 2025 (actual)
- Study completion
- 15 Jul 2026 (actual)
- First posted
- 8 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational is to analyze the relationship between levels of interleukin-18 (IL-18), interleukin (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), interleukin-10 (IL-10), transforming growth factor beta (TGF-β), Nucleotide-binding oligomerization domain -like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), caspase-1, Sirtuin 1 (SIRT-1), Long noncoding RNA (lncRNA) small nucleolar RNA host gene 5 (SNHG5), and maternally expressed gene 3 (MEG3) in saliva, serum, and peripheral mononuclear blood cell (PMBC)in patients with periodontitis and smokers, to examine the changes in these biomarkers after non surgical periodontal treatment (NSPT), and to evaluate potential confounders that may mediate this relationship.
The main questions it aims to answer are:
question 1: Is there a relationship between the biomarkers mentioned above and periodontitis and smoking? question 2:How do the above-mentioned biomarkers change after NSPT in smokers and non-smokers?
Detailed description
There will be 4 groups in the study: Non-smoking periodontitis (NSP), smoking periodontitis (SP), non-smoking healthy control (HC), and smoking healthy control (HCS).
The periodontitis groups in the study (NSP and SP) will include patients diagnosed with Stage II and III, generalized, Grade B, C periodontitis clinically based on the consensus report of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions, and systemically healthy individuals. Patients with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. Patients with periodontal disease-related tooth loss ≤4 teeth will be included. Disease progression rate will be graded as B or C Class based on direct evidence of disease progression confirmed by panoramic radiographs and evidence of indirect destruction proportional to biofilm accumulations. In the smoking periodontitis group (SP) and smoking healthy group (HCS), participants who reported smoking >10 cigarettes per day for >5 years will be included, while participants in the non-smoking groups (NSP and HC) will be those who reported never smoking.
Clinical Measurements and Non-surgical Periodontal Treatment
Saliva and serum samples will be collected from all patients initially and 3 months after NSPT. Clinical parameters will also be recorded initially and at the 3rd month. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing. Examiner calibration will be provided before starting the study on a small pilot population to achieve consistent intra-examiner accuracy. After the collection of baseline samples and clinical parameter records, all patients will receive initial periodontal treatment, including patient education, full-mouth scaling, and root planing (SRP), and oral hygiene instructions from the same experienced clinician (ZTE).
Laboratory Measurement
Each patient will be instructed to abstain from eating, drinking, and oral hygiene practices for 12 hours before sampling. Serum and saliva samples will be collected from each patient between 8:00 and 10:00 in the morning before dental examination.
Blood Sampling: In the scope of the study, a total of 5 mL of blood will be collected from the antecubital vein of each individual by an expert nurse from the Department of Periodontology.
For serum sampling, venous puncture will be performed, and blood samples will be collected, immediately cooled on ice, and centrifuged at 4°C (800 rpm for 10 minutes). After the collection of saliva samples, they will be centrifuged immediately at 4°C (1000 rpm for 2 minutes). Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time polymerase chain reaction (RT-PCR).
IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels in PMBC will be evaluated using RT-PCR. All analysis steps for each kit will be evaluated using the protocol recommended by the manufacturer.
Statistical Analysis:
Statistical analysis will be performed using commercially available software (SPSS version 22.0, SPSS). In this study, a significance value (p-value) of <0.05 will be used. This study is designed as a prospective controlled clinical trial. The sample size of the study was calculated using the R Statistical Language program (version 4.1.2; The R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org). It was planned to include at least 25 individuals in each group for One-Way Analysis of Variance analysis to be conducted with a significance level of 5%, statistical power of 80%, and effect size of 0.4 (Cohen's f=0.4) to determine if there is a significant difference in inflammatory factors between the study groups (smoking periodontitis, smoking periodontally healthy, non-smoking periodontitis, non-smoking periodontally healthy).
Longitudinal analyses will include data only from patients who complete the entire study protocol.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Non-smoking periodontitis (NSP) | – | Diagnostic Test: Before non-surgical periodontal treatment, Procedure: non-surgical periodontal treatment, Diagnostic Test: 3rd month after non-surgical periodontal treatmentparticipants who reported never smoking, with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. |
| smoking periodontitis (SP) | – | Diagnostic Test: Before non-surgical periodontal treatment, Procedure: non-surgical periodontal treatment, Diagnostic Test: 3rd month after non-surgical periodontal treatmentparticipants who reported smoking >10 cigarettes per day for >5 years with clinical attachment loss ≥3 mm in >30% of sites, with probing depth ≥5 mm in at least six teeth, and with radiographic bone loss extending to or beyond the middle third of the root in the coronal third will be included. |
| non-smoking periodontal health (HC) | – | Diagnostic Test: Before non-surgical periodontal treatmentparticipants who reported never smoking and periodontal healthy. |
| smoking periodontal health (HCS) | – | Diagnostic Test: Before non-surgical periodontal treatmentparticipants who reported smoking >10 cigarettes per day and periodontal healthy. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- This study is planned to be conducted with 100 individuals aged between 18 and 65 who apply to the Department of Periodontology, Faculty of Dentistry, Necmettin Erbakan University, for various reasons. The eligibility of individuals to be included in the study will be evaluated by Dr. Zeynep TAŞTAN EROĞLU at the Periodontology Clinic of NEU Faculty of Dentistry.
Key inclusion criteria (4 listed)
- Being between the ages of 18 and 65
- Being diagnosed as "periodontally healthy" or "periodontitis" based on periodontal examination
- Not having any accompanying systemic diseases (such as diabetes, cardiovascular diseases, etc.)
- Agreeing to participate in the study
Key exclusion criteria (6 listed)
- Use of contraceptive medications
- Use of anti-inflammatory, antibiotic, immunosuppressive, or other medications - that could affect the study outcomes within the previous 6 months
- History of excessive alcohol consumption
- Pregnancy or breastfeeding
- Undergoing periodontal treatment within the previous 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Before non-surgical periodontal treatmentClinical Measurements and Laboratory Measurement Saliva and serum samples will be collected from all patients initially. Clinical parameters will also be recorded initially. Plaque index (PI) and gingival index (GI) will be recorded at four sites per tooth. Full-mouth probing depth (PD) and clinical attachment level (CAL) will be detailed per tooth at six sites, and the percentage of bleeding areas will be recorded as present or absent within 20 seconds after probing using a binary scoring system. A calibrated periodontologist (ZTE) will record all clinical parameters using manual probing. Following sampling, both serum and saliva samples will be stored at -80°C until analysis. Concentrations of NLRP3, ASC, caspase-1, IL-18, IL-1beta, TNF-alfa, IL-10, TGF-beta, and SIRT-1 will be analyzed by specific enzyme-linked immunosorbent assay (ELISA) kits in both serum and saliva samples. LncRNA SNHG5 and MEG3 will be examined using Real-time PCR. | Diagnostic test | Non-smoking periodontitis (NSP), non-smoking periodontal health (HC), smoking periodontal health (HCS), smoking periodontitis (SP) |
| non-surgical periodontal treatmentTreatment will be performed using ultrasonic devices followed by root planing with gracey curettes. SRP will be completed in two visits, each consisting of quadrants every 2 days. Oral hygiene instructions will include demonstrating proper brushing techniques and the use of interdental cleaning aids as needed. Saliva and serum samples will be collected again at the 3-month follow-up visit, all clinical parameter records will be repeated by the same clinician (ZTE), and oral hygiene instructions will be reconfirmed as needed. After the collection of 3-month records and samples, all patients with persistent pockets will be subjected to a standard periodontitis treatment protocol. | Procedure or surgery | Non-smoking periodontitis (NSP), smoking periodontitis (SP) |
| 3rd month after non-surgical periodontal treatmentAll clinical and laboratory evaluations described under the heading "Before non-surgical periodontal treatment" will be repeated in the 3rd month after NSPT. | Diagnostic test | Non-smoking periodontitis (NSP), smoking periodontitis (SP) |
Primary outcome
Pre-treatment clinical and laboratory evaluation
Time frame: baseline
Comparison of clinical measurements and IL-18, IL-1beta, TNF-alpha, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels of the 4 groups in the study
Comparison of clinical measurements and laboratory measurements at 3 months post-treatment
Time frame: 3rd month after NSPT
Comparison of clinical measurements and IL-18, IL-1beta, TNF-alpha, IL-10, TGF-beta, NLRP3, SIRT-1, lncRNA SNHG5, and MEG3 levels of periodontitis groups (NSP and SP) at the 3rd month after treatment
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
Related trials for Periodontitis, Adult
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Not yet recruitingObservational study
Evaluation of Changes in Oral Health-related Quality of Life During the Treatment of Periodontitis.
Periodontitis, Adult, Periodontitis
Not yet recruiting
Sonic Irrigation Activation for Postoperative Pain After Root Canal Treatment
Asymptomatic Apical Periodontitis
Active, not recruiting
Utilization of a Videoscope in Periodontal Regeneration
Chronic Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontitis, Adult, run by Necmettin Erbakan University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pre-treatment clinical and laboratory evaluation (time frame: baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.